Zambia is a sub-sahara African nation that is located in the HIV belt where there is a very high incidence of HIV infection.. In the general population, it is estimated that both 30 to 40% may be infected by HIV. Our preliminary study with at randomized cohort of pregnant women, delivering at the University of Zambia Teaching Hospital in Lusaka, Zambia, showed an HIV seroprevalence rate of about 32%. It is expected that many of the babies born to these women will also be infected by HIV. The HIV isolated from this region of the world are the non-major subgroup, such as subgroup Clade C. Thus, there is an urgent need to develop inexpensive and effective means to prevent perinatal transmission of Clade C viruses. This program project proposes to test a combination of active and passive immunoprophylaxis treatments on newborns to prevent vertical transmission, focusing on the Clade C virus, using the SHIV virus to test in the macaque model. This core will make use of an ongoing study in Zambia to study the transmission of Kaposi's sarcoma associated herpesviruses, KSHV, or human herpesvirus-8, HHV-8. Using the developed infrastructure at the University Teaching Hospital in Zambia, its ongoing recruitment of mother-infant pairs at delivery, as well as follow-up studies to collect matched mother-infant pairs, Clade C or non-Clade B local viral isolates to support the program project.
The specific aims are: 1) To recruit mother/infant pairs into this study; to identify those that have transmitted HIV vertically. 2) To isolated both the mother/infant viral pairs. 3) To PCR amplify, clone, and determine the viral Clade subgroup by sequence analysis. 4) To clone and express the HIV env genes, and to determine whether the cloned env genes are functional by pseudotyping. 5) To provider the cloned functional env genes from the infants' HIV isolates, the paired Clade C or local HIV Clade strains, as well as whole blood from Clade C infected individuals to the Projects 1 and 2, as well as Cores of this program project.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI048240-02
Application #
6474985
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-06-01
Project End
2002-05-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
$171,469
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Bachler, Barbara C; Humbert, Michael; Lakhashe, Samir K et al. (2013) Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology 10:63

Showing the most recent 10 out of 77 publications